Serum syndecan-1: a new independent prognostic marker in multiple myeloma

被引:187
作者
Seidel, C [1 ]
Sundan, A
Hjorth, M
Turesson, I
Dahl, IMS
Abildgaard, N
Waage, A
Borset, M
机构
[1] Norwegian Univ Sci & Technol, Inst Canc Res & Mol Biol, Norwegian Canc Soc, Med Tekn Senter, N-7489 Trondheim, Norway
[2] Norwegian Univ Sci & Technol, Univ Hosp, Sect Hematol, N-7489 Trondheim, Norway
[3] Lidkoping Hosp, Dept Med, Lidkoping, Sweden
[4] Malmo Univ Hosp, Dept Med, Malmo, Sweden
[5] Univ Tromso Hosp, Sect Hematol, N-9012 Tromso, Norway
[6] Aarhus Univ Hosp, Dept Med & Hematol, DK-8000 Aarhus, Denmark
关键词
D O I
10.1182/blood.V95.2.388
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Serum samples drawn at diagnosis from 174 myeloma patients were analyzed for the presence of the heparin sulfate proteoglycan, syndecan-1, Syndecan-1 was elevated in 79% of patients (median, 643 units/mL) compared with 40 healthy controls (median, 128 units/mL), P < .0001. Serum syndecan-1 correlated with the following: serum creatinine, secretion of urine M-component over the course of 24 hours, soluble interleukin-6 (IL-6) receptor, C-terminal telopeptide of type I collagen, beta(2)-microglobulin, percentage of plasma cells in the bone marrow, disease stage, and serum M-component concentration. In order to evaluate syndecan-1 as a prognostic marker in multiple myeloma, it was entered into a multivariate Cox regression model. Data from 138 patients were available for this analysis. As a continuous variable, syndecan-1 was an independent prognostic parameter in addition to serum beta(2)-microglobulin and World Health Organization performance status. When syndecan-1 was dichotomized by the best cutoff (66th percentile, 1170 units/mL), the survival difference between the groups was highly significant: "high" syndecan-1 group had a median survival of 20 months, and the "low" syndecan-1 group had a median of 44 months (P < .0001). We conclude that syndecan-1 is a new independent prognostic parameter in multiple myeloma, and its role in prognostic classification systems should be further investigated. (Blood. 2000;95:388-392) (C) 2000 by The American Society of Hematology.
引用
收藏
页码:388 / 392
页数:5
相关论文
共 32 条
[1]  
BATAILLE R, 1992, BLOOD, V80, P733
[2]  
BOCCADORO M, 1993, BLOOD, V82, P3507
[3]  
BORSET M, 1993, BRIT J HAEMATOL, V85, P446
[4]  
Carey DJ, 1997, BIOCHEM J, V327, P1
[5]  
COX DR, 1982, JR STAT SOC, V34
[6]   The use of biological variables to predict outcome in multiple myeloma [J].
Davies, FE ;
Jack, AS ;
Morgan, GJ .
BRITISH JOURNAL OF HAEMATOLOGY, 1997, 99 (04) :719-725
[7]   Elevated levels of shed syndecan-1 correlate with tumour mass and decreased matrix metalloproteinase-9 activity in the serum of patients with multiple myeloma [J].
Dhodapkar, MV ;
Kelly, T ;
Theus, A ;
Athota, AB ;
Barlogie, B ;
Sanderson, RD .
BRITISH JOURNAL OF HAEMATOLOGY, 1997, 99 (02) :368-371
[8]   Syndecan-1 is a multifunctional regulator of myeloma pathobiology: Control of tumor cell survival, growth, and bone cell differentiation [J].
Dhodapkar, MV ;
Abe, E ;
Theus, A ;
Lacy, M ;
Langford, JK ;
Barlogie, B ;
Sanderson, RD .
BLOOD, 1998, 91 (08) :2679-2688
[9]  
DURIE BGM, 1990, BLOOD, V75, P823
[10]  
DURIE BGM, 1975, CANCER, V36, P842, DOI 10.1002/1097-0142(197509)36:3<842::AID-CNCR2820360303>3.0.CO